Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunoradiotherapy as an Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 8, Pages 2178
Publisher
MDPI AG
Online
2020-08-06
DOI
10.3390/cancers12082178
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiotherapy: A prospective-retrospective analysis of 3 phase I/II Trials
- (2020) Dawei Chen et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Combining Immunotherapy with Radiation Therapy in Non–Small Cell Lung Cancer
- (2020) Kelly Fitzgerald et al. Thoracic Surgery Clinics
- Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
- (2020) Dawei Chen et al. Journal for ImmunoTherapy of Cancer
- Randomized phase I trial to evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and stereotactic body Radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study).
- (2020) Jyoti D. Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
- (2020) David A. Palma et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects
- (2019) Slavisa Tubin et al. Radiation Oncology
- TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
- (2019) María E. Rodríguez-Ruiz et al. MOLECULAR CANCER THERAPEUTICS
- Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer
- (2019) P. K. Cheema et al. Current Oncology
- Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review
- (2019) Rodolfo Chicas-Sett et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
- (2019) Daniel R. Gomez et al. JOURNAL OF CLINICAL ONCOLOGY
- OC-0060 I-SABR induces local and abscopal responses in metastatic patients after failure to ICI treatment
- (2019) R. Chicas Sett et al. RADIOTHERAPY AND ONCOLOGY
- Stereotactic body radiation therapy versus surgery for early stage non-small cell lung cancer: clearing a path through an evolving treatment landscape
- (2019) J. Isabelle Choi et al. Journal of Thoracic Disease
- Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial
- (2019) S. Peters et al. LUNG CANCER
- Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer
- (2019) Joshua M. Bauml et al. JAMA Oncology
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Combining immunotherapy and radiotherapy for the STAR treatment
- (2019) Jordan A. Torok et al. Nature Reviews Clinical Oncology
- What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?
- (2019) Eric G. Nesbit et al. Translational Lung Cancer Research
- 1457PDEfficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC: Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial
- (2019) S Peters et al. ANNALS OF ONCOLOGY
- Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer
- (2019) Gishan Ratnayake et al. Asia-Pacific Journal of Clinical Oncology
- Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer
- (2019) James W. Welsh et al. Journal of Thoracic Oncology
- OA13.05 NADIM Study: Updated Clinical Research and Outcomes
- (2019) M. Provencio et al. Journal of Thoracic Oncology
- Abscopal effect in lung cancer: three case reports and a concise review
- (2019) Elena Garelli et al. Immunotherapy
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
- (2018) Silvia C. Formenti et al. CLINICAL CANCER RESEARCH
- Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
- (2018) Ariel E. Marciscano et al. CLINICAL CANCER RESEARCH
- Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
- (2018) Caitlin A. Schonewolf et al. LUNG CANCER
- Safety of combining radiotherapy with immune-checkpoint inhibition
- (2018) William L. Hwang et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
- (2018) Greg Andrew Durm et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer
- (2018) I. Desideri et al. Clinical & Translational Oncology
- Radiotherapy induces responses of lung cancer to CTLA-4 blockade
- (2018) Silvia C. Formenti et al. NATURE MEDICINE
- Time to abandon single-site irradiation for inducing abscopal effects
- (2018) Eric D. Brooks et al. Nature Reviews Clinical Oncology
- Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
- (2018) Zachary S. Buchwald et al. Frontiers in Oncology
- Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies
- (2017) J.W. Welsh et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Combined Immune Checkpoint Blockade and Radiation Therapy: Timing and Dose Fractionation Associated with Greatest Survival Duration Among Over 750 Treated Patients
- (2017) R. Samstein et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
- (2017) Hua Liang et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy
- (2017) Sameera S. Kumar et al. Frontiers in Oncology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells
- (2016) Chad Tang et al. CLINICAL CANCER RESEARCH
- Systematic review of case reports on the abscopal effect
- (2016) Yazan Abuodeh et al. CURRENT PROBLEMS IN CANCER
- The immune mechanisms of abscopal effect in radiation therapy
- (2016) G. Daniel Grass et al. CURRENT PROBLEMS IN CANCER
- PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2016) Suresh Senan et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- GILT—A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer
- (2016) Michael Flentje et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
- (2016) Kristina H. Young et al. PLoS One
- Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non–Small Cell Lung Cancer
- (2015) Virag K. Dandekar et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Abscopal effects of radiation therapy: A clinical review for the radiobiologist
- (2015) Shankar Siva et al. CANCER LETTERS
- TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
- (2015) Claire Vanpouille-Box et al. CANCER RESEARCH
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
- (2015) Luis Paz-Ares et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non–Small-Cell Lung Cancer: KCSG-LU05-04
- (2015) Jin Seok Ahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
- (2015) Jeffrey D Bradley et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toxicity Patterns With Immunomodulating Antibodies and Their Combinations
- (2015) John B.A.G. Haanen et al. SEMINARS IN ONCOLOGY
- Role of Local Radiation Therapy in Cancer Immunotherapy
- (2015) Sandra Demaria et al. JAMA Oncology
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Combinations of Immunotherapy and Radiation in Cancer Therapy
- (2014) Ralph E. Vatner et al. Frontiers in Oncology
- IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor
- (2013) Scott A. Gerber et al. AMERICAN JOURNAL OF PATHOLOGY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Cancer and Radiation Therapy: Current Advances and Future Directions
- (2012) Rajamanickam Baskar et al. International Journal of Medical Sciences
- Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
- (2012) A. Gupta et al. JOURNAL OF IMMUNOLOGY
- Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis
- (2012) Sashendra Senthi et al. LANCET ONCOLOGY
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
- (2011) W. J. Curran et al. JNCI-Journal of the National Cancer Institute
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
- (2010) Anne Aupérin et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Radiotherapy and Implications for the Next Century: A Historical Perspective
- (2009) P. P. Connell et al. CANCER RESEARCH
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
- (2009) Kathy S Albain et al. LANCET
- Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology
- (2008) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
- (2008) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started